BR112021021663A2 - Inibidores da via rank em combinação com inibidores de cdk - Google Patents

Inibidores da via rank em combinação com inibidores de cdk

Info

Publication number
BR112021021663A2
BR112021021663A2 BR112021021663A BR112021021663A BR112021021663A2 BR 112021021663 A2 BR112021021663 A2 BR 112021021663A2 BR 112021021663 A BR112021021663 A BR 112021021663A BR 112021021663 A BR112021021663 A BR 112021021663A BR 112021021663 A2 BR112021021663 A2 BR 112021021663A2
Authority
BR
Brazil
Prior art keywords
inhibitors
combination
cdk
rank pathway
methods
Prior art date
Application number
BR112021021663A
Other languages
English (en)
Inventor
António Marques Da Costa Luis
Cristina Cara De Anjo Casimiro Sandra
Original Assignee
Inst De Medicina Molecular Joao Lobo Antunes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst De Medicina Molecular Joao Lobo Antunes filed Critical Inst De Medicina Molecular Joao Lobo Antunes
Publication of BR112021021663A2 publication Critical patent/BR112021021663A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

inibidores da via rank em combinação com inibidores de cdk. são aqui proporcionadas composições farmacêuticas compreendendo i) um inibidor da via rank em combinação com ii) um inibidor de cdk e métodos relacionados. são aqui proporcionados métodos de aumentar ou restaurar uma capacidade de resposta ou sensibilidade de uma célula cancerígena ao tratamento com um inibidor de cdk e métodos de tratar um sujeito com resistência ou sensibilidade reduzida ao tratamento com um inibidor de cdk.
BR112021021663A 2019-04-30 2020-04-24 Inibidores da via rank em combinação com inibidores de cdk BR112021021663A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840810P 2019-04-30 2019-04-30
PT11548319 2019-04-30
PCT/PT2020/050017 WO2020222668A1 (en) 2019-04-30 2020-04-24 Rank pathway inhibitors in combination with cdk inhibitors

Publications (1)

Publication Number Publication Date
BR112021021663A2 true BR112021021663A2 (pt) 2022-05-17

Family

ID=70775461

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021663A BR112021021663A2 (pt) 2019-04-30 2020-04-24 Inibidores da via rank em combinação com inibidores de cdk

Country Status (9)

Country Link
US (1) US20220195059A1 (pt)
EP (1) EP3962945A1 (pt)
JP (1) JP2022530241A (pt)
KR (1) KR20220002316A (pt)
AU (1) AU2020266083A1 (pt)
BR (1) BR112021021663A2 (pt)
CA (1) CA3132656A1 (pt)
MX (1) MX2021013271A (pt)
WO (1) WO2020222668A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240254245A1 (en) * 2021-05-12 2024-08-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN115718192B (zh) * 2022-11-25 2025-02-14 浙江洛兮医疗科技有限公司 一种免疫组化即用型pd-l1抗体试剂
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
CN117643591A (zh) * 2023-02-23 2024-03-05 四川大学华西医院 一种用于mycn扩增型rb的抑制剂及抑制效果验证方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581916A (en) 1897-05-04 Harvester
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
ES2165346T3 (es) 1989-09-15 2002-03-16 Res Triangle Inst Analogos de 10,11-metilendioxi-20(rs)-camptotecina y 10,11-metilendioxi-20(s)-camptotecina.
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｉｐアンタゴニストを用いる併用療法
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2003033499A2 (en) 2001-10-15 2003-04-24 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
NZ535232A (en) 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
US6818663B2 (en) 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
WO2004069137A2 (de) 2003-02-07 2004-08-19 Ge Bayer Silicones Gmbh & Co. Kg Verwendung von polyamino- und/oder polyammonium-polysiloxancopolymeren
WO2004097048A1 (en) 2003-04-28 2004-11-11 Canon Kabushiki Kaisha Process for assay of nucleic acid by competitive hybridization using a dna microarray
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
CA3025264A1 (en) * 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
EP3654967A4 (en) * 2017-07-21 2021-04-21 Eisai R&D Management Co., Ltd. USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
JP2022530241A (ja) 2022-06-28
CA3132656A1 (en) 2020-11-05
EP3962945A1 (en) 2022-03-09
KR20220002316A (ko) 2022-01-06
MX2021013271A (es) 2022-01-06
WO2020222668A1 (en) 2020-11-05
AU2020266083A1 (en) 2021-09-23
US20220195059A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
MX2021013271A (es) Inhibidores de la via rank en combinacion con inhibidores de cdk.
Rouschop et al. PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS
Xiao et al. Metformin promotes innate immunity through a conserved PMK-1/p38 MAPK pathway
BR112021019722A2 (pt) Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico
BR112022022401A2 (pt) Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade
Gallorini et al. HEMA‐induced cytotoxicity: oxidative stress, genotoxicity and apoptosis
BR112023020182A2 (pt) Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula
Fong et al. Substance P enhances collagen remodeling and MMP‐3 expression by human tenocytes
JOP20200050A1 (ar) عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام
EA201991985A1 (ru) Конъюгаты антитело-лекарственное средство (калс) на основе ингибиторов гдац и применение в терапии
PH12019502594A1 (en) Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112018067379A2 (pt) conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição.
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
Drira et al. Sakuranetin induces melanogenesis in B16BL6 melanoma cells through inhibition of ERK and PI3K/AKT signaling pathways
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
BR112018012022A2 (pt) ?composição, e, método para tratamento ou redução do risco de colestase intra-hepática?
BR112019011365A2 (pt) métodos para tratar câncer
BR112022001341A2 (pt) Inibidores de enzima
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
BR112022022036A2 (pt) Construtos de ligação ao antígeno que têm como alvo her2 e usos dos mesmos
Park et al. Oral administration of glycine and leucine dipeptides improves skin hydration and elasticity in UVB-irradiated hairless mice
BR112016007592A2 (pt) proteína de ligação biespecífica que se liga a pelo menos dois alvos, conjugado de proteína de ligação biespecífica, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, método para produzir uma proteína de ligação biespecífica, método para determinar a reatividade de um paciente a um agente terapêutico que tem capacidade para modular a atividade de um tlr, método para ativar ou inibir células responsivas a tlr9, método para tratar um paciente que precisa de ativação de tlr9 ou inibição de tlr e método para identificar um inibidor ou estimulador de sinalização de tlr

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2824 DE 18/02/2025.